Description
STERIS’ $400 Million Healthcare Backlog Puts Equipment Demand Back In Focus!
STERIS plc reported financial results for fiscal year 2026 reflecting a mixed but overall steady performance amid ongoing economic and operational challenges. The company posted a 7% increase in reported revenue in the fourth quarter and 9% growth for the full year, with constant currency organic revenue growth at 5% for the quarter and 7% for the year. Growth was driven primarily by volume increases and pricing gains, with approximately 230 basis points of price benefit in Q4. Despite inflationary pressures, higher tariffs, and supply chain complexities, gross margin declined slightly by 30 basis points to 44% in Q4, while EBIT margin was 24.2%, just 60 basis points lower than the prior year’s fourth quarter but still a high for the fiscal year. Adjusted earnings per diluted share grew 3% year-over-year in Q4 to $2.83, reaching $10.
